From the Departments of Neuropathology (I.B., G.H., R.C., K.K.) and Neurosurgery (K.R.) and the Epilepsy Center (H. Hamer, H.S.), University Hospital Erlangen, Erlangen, the Epilepsy Center Bethel, Krankenhaus Mara, Bielefeld (C.G.B., M.P.), the Departments of Epileptology (C.E., G.W.) and Neuropathology (A.B.), University of Bonn Medical Center, and Medical Faculty, University of Bonn (J.S.), Bonn, the Neuropediatric Clinic, Epilepsy Center for Children and Adolescents, Schön Klinik Vogtareuth, Vogtareuth (T.P., H. Holthausen, M.K., P.A.W.), the Epilepsy Center Berlin–Brandenburg, Berlin (H.J.M.), the Epilepsy Center (G.H., A.S.-B.) and Department of Neurosurgery (J.Z., D.H.H.), University Hospital, and the Department of Neuroradiology, Medical Center–University of Freiburg, and Faculty of Medicine, University of Freiburg (H.U.) Freiburg, Kork Epilepsy Center, Kehl-Kork (B.J.S., T.B.), the Departments of Neuropathology (S.V.) and Neurology (U.R.), University Hospital Greifswald, Greifswald, the Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Tübingen (H.L., Y.W.), the Department of Neurology, University of Ulm, Ulm (H.L., Y.W.), the Epilepsy Center, Department of Neurology, Ludwig-Maximilians-University Hospital, Munich (S.N., E.H., P.A.W.), Sächsisches Epilepsiezentrum Radeberg, Radeberg (T.M., M.L.), Epilepsy Center Frankfurt Rhine–Main and the Department of Neurology, Goethe University, Frankfurt am Main (F.R., A.H.), the Epilepsy Center Hessen–Marburg, Philipps–University Marburg, Marburg (F.R., A.H.), and the Department of Social Medicine, Occupational and Environmental Dermatology, Heidelberg University, Heidelberg (T.L.D.) — all in Germany; the Clinical Epileptology and Experimental Neurophysiology Unit (R.S.) and the Department of Neurophysiology, Epilepsy Center (G.A.), IRCCS Foundation, Neurological Institute C. Besta, and the Claudio Munari Epilepsy Surgery Center, Niguarda Hospital (L.T., G.L.R.), Milan, and the Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer–University of Florence, Florence (R.G., C.B.) — all in Italy; Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery (K.P.B., F.L.), and the Department of (Neuro)Pathology (E.A.), University Medical Center Utrecht, Utrecht, the Department of Neurosurgery, VU University Medical Center (J.C.B.), and the Department of (Neuro)Pathology, Academic Medisch Centrum, University of Amsterdam (E.A., A.M.), and the Department of (Neuro)Pathology, VU University Medical Center (E.A., A.M.), Amsterdam, Stichting Epilepsie Instellingen Nederland, Heemstede (E.A.), and the Department of Neurosurgery, Academic Center for Epileptology, Maastricht University Medical Center, Maastricht (O.S.) — all in the Netherlands; the Department of Neurosurgery, Sainte-Anne Hospital, and Paris Descartes University, Paris (F.C.), the Department of Neurology, Michallon Hospital, GIN INSERM Unité 836, Grenoble Alpes University, Grenoble (P. Kahane), and the Department of Clinical Epileptology, Sleep Disorders and Functional Neurology in Children, University Hospitals of Lyon, and the Brain Dynamics and Cognition team, Lyon Neurosciences Research Center, Lyon (A.A., A.U.-C.) — all in France; the Departments of Neuropathology (M.T.) and Clinical and Experimental Epilepsy (M.C.W., S.M.S., J.S.D., A.W.M.), UCL Institute of Neurology, and the Developmental Biology and Cancer Programme (T.S.J.) and Developmental Neurosciences Program (J.H.C.), UCL–Great Ormond Street Institute of Child Health, and the Department of Histopathology, Great Ormond Street Hospital for Children (T.S.J.), London, and Young Epilepsy, Lingfield (J.H.C.) — all in the United Kingdom; the Departments of Neurology (C.Ö.) and Pathology (B.O.), Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey; the Department of Pediatric Neurology, Motol Epilepsy Center, Charles University in Prague, and the 2nd Faculty of Medicine, Motol University Hospital, Prague, Czech Republic (P. Krsek); the Department of Anatomical Pathology, Hospital Pedro Hispano, Matosinhos (M.H.), and the Laboratory of Neuropathology, Department of Neurosciences, Hospital de Santa Maria–Centro Hospitalar de Lisboa Norte, Lisbon (J.P.) — both in Portugal; the Epilepsy Unit, Child Neurology Department, Hospital San Juan de Dios, Barcelona (A.A., A.U.-C.); the Department of Pediatrics, Medical University Vienna, Vienna (M.F., A.M.), the Departments of Neurology (E.T.) and Neurosurgery (P.A.W.), Christian Doppler Medical Center, Paracelsus Medical University, Center for Cognitive Neuroscience, Salzburg, and the Department of Neurology I, Neuromed Campus, Kepler Universitätsklinikum, Linz (T.J.O.) — all in Austria; the Swiss Epilepsy Center and Department of Neurology, University Hospital, Zurich, Switzerland (T.G.); the Department of Neurology, Hospital Ruber Internacional, Madrid (A.G.-N., R.T.D.); and the Neurosurgical Department (B.Z.) and Epilepsy Monitoring Unit (K.G.), St. Luke's Hospital, Thessaloniki, Greece.
A complete list of members of the European Epilepsy Brain Bank (EEBB) Consortium is provided in the Supplementary Appendix, available at NEJM.org.
Address reprint requests to Dr. Blumcke at the Institute of Neuropathology, University Hospital Erlangen, Schwabachanlage 6, D–91054 Erlangen, Germany, or at [email protected].
Supported by the European Union (FP7 DESIRE GA grant 602531, to Drs. Blumcke, Spreafico, Haaker, Tassi, Guerrini, and Barba; FP7 EPITARGET GA grant 602102, to Drs. Becker, Aronica, Walker, and Sisodiya; FP7 EPISTOP grant 602391, to Dr. Aronica; and FP7 EpimiRNA GA grant 602130, to Drs. Hamer and Rosenow); EpiGENet (DFG Bl 421/3-1, to Dr. Blumcke); the Johannes and Frieda Marohn Foundation of the Friedrich-Alexander University Erlangen-Nuremberg (support to Dr. Blumcke); the Austrian Science Fund (FWF grant J3499, to Dr. Mühlebner and grants P21636, P24367, DK W 1233-G17, KLI543-B27, and KLI12-B00, to Dr. Trinka); the Italian Ministry of Health (grant RF-2011-02350578, to Drs. Spreafico, Tassi, and Guerrini, and grant RF-2010-2309954, to Dr. Barba), the National Institute for Health Research University College London Hospitals Biomedical Research Centre (support to Drs. Thom, Walker, Sisodiya, Duncan, and McEvoy); Great Ormond Street Hospital Children's Charity, the Brain Tumour Charity, Children with Cancer, Higher Education Funding Council for England, and the National Institute for Health Research (support to Dr. Jacques); the Anniversary Fund of the Central Bank of the Republic of Austria (grant ÖNB-12036, to Dr. Feucht); and Fundación Gmp (support to Dr. Gil-Nagel).
Dr. Kobow reports receiving lecture fees from Nutricia; Dr. Bien, receiving lecture fees, consulting fees, and travel support from Eisai, UCB, and Desitin, grant support and travel support from Griflos, grant support and lecture fees from Diamed and Fresenius Medical Care, lecture fees from Euroimmun, and consulting fees from Laboratory Krone; Dr. Elger, receiving honoraria and consulting fees from UCB, Desitin, Bial, and Eisai; Dr. Hamer, receiving advisory board fees and lecture fees from UCB, Desitin, Eisai, and Novartis, advisory board fees from Cerbomed, and lecture fees from Hexal and Boehringer Ingelheim; Dr. Stefan, receiving honoraria from Eisai, Elekta, Novartis, LivaNova, and Desitin; Dr. Walker, receiving grant support from Vitaflo, lecture fees and advisory board fees from Eisai and UCB Pharma, consulting fees from GlaxoSmithKline and Pfizer, lecture fees from Special Products, advisory board fees from Sanofi, holding a patent on “Therapeutic use of compounds” (WO 2012069790) licensed to Vitaflo, and holding a patent on “Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures” (WO 2015136247); Dr. Duncan, receiving grant support from Wellcome Trust; Dr. Schulze-Bonhage, receiving grant support from Bial, lecture fees and consulting fees from Eisai and UCB, and consulting fees from Precisis; Dr. Urbach, receiving lecture fees from Bayer, Bracco, Stryker, and UCB Pharma; Dr. Lerche, receiving consulting fees, lecture fees, and travel support from Bial, Eisai, and UCB Pharma, lecture fees and travel support from Desitin, and consulting fees from Biomarine; Dr. Jacques, serving as a director and holding equity in Neuropath, and serving as a director, company secretary, and holding equity in Repath; Dr. Cross, receiving grant support (paid to her department) from Zogenix, GW Pharma, and Vitaflo, lecture fees (paid to her department) from Shire and Nutricia, and advisory board fees (paid to her department) from Eisai and GlaxoSmithKline; Dr. Grunwald, receiving lecture fees from Desitin, Eisai, and UCB; Dr. Gil-Nagel, receiving grant support and lecture fees from Bial and UCB Pharma, lecture fees from Eisai, Sanofi, and Zogenix, and advisory fees from Esteve; Dr. Rosenow, receiving advisory board fees, lecture fees, and travel support from UCB Pharma, serving on an advisory board for Shire, Eisai, Desitin Arzneimittel, Bial, Cerbomed, and Sandoz, travel support from Novartis Japan, lecture fees from Bayer Vital and Verband der Forschender Arzneimittelhersteller, and grant support from the Detlev-Wrobel-Fonds for Epilepsy Research; Dr. von Oertzen, receiving advisory board fees and travel support from Eisai Pharma, grant support, travel support, and serving on an advisory board for UCB Pharma and Novartis, travel support from Medtronic, grant support from Grossegger and Drbal, serving on an advisory board for Roche, Biogen, and Sanofi-Genzyme, and serving as an expert witness for LivaNova. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This report describes independent research by the National Institute for Health Research (NIHR) Biomedical Research Centre Funding Scheme. The views expressed in this article are those of the authors and not necessarily those of the National Health Service, the NIHR, or the U.K. Department of Health.